01—Abstract
Summary
Summary of the 8-K filed July 18, 2024. Cited figures are marked; the original filing is the authoritative source.
Guardant Health (Nasdaq: GH) filed an 8-K on July 18, 2024 to disclose the appointment of Dr. Manuel Hidalgo Medina to its Board of Directors.
The Board increased its size from eight to nine members on July 17, 2024, and appointed Dr. Hidalgo as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. He was also placed on the Nominating and Corporate Governance Committee. The filing is a governance event rather than a financial disclosure, and it includes no reported financial results, guidance, or material operational changes.
Dr. Hidalgo is Chief of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, and he is the Walter B. Wriston Professor of Pancreatic Cancer Research. He has more than 20 years of experience in translational and clinical anticancer drug development, with a focus on gastrointestinal cancers and early clinical development for pancreatic cancer.
He previously led hematology at Beth Israel Deaconess Medical Center and served as Clinical Director of the Rosenberg Clinical Cancer Center from 2015 to 2019. He also sits on the board of Bristol-Myers Squibb. For Guardant, his oncology expertise adds clinical and drug-development perspective to the board, which is relevant to a company whose tests span screening, recurrence monitoring, and treatment selection.
His compensation follows the standard non-employee director program. He receives a stock option award and a restricted stock unit award, each valued at $362,500,a vesting over roughly three years, with one-quarter vesting at the first anniversary and the remainder vesting monthly thereafter. The Company is also entering into its standard indemnification agreement with him.
The filing reports no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K, and no arrangements with other persons under which he was selected. Investors should view this as a routine board refresh with limited direct financial impact.
02—Key points
Key Highlights
- Board expanded from eight to nine directors, with Dr. Manuel Hidalgo Medina appointed as a Class II director effective July 17, 2024.
- Dr. Hidalgo's term runs until the 2026 Annual Meeting of Stockholders, and he joins the Nominating and Corporate Governance Committee.
- Dr. Hidalgo brings more than 20 years of translational and clinical anticancer drug development experience, with emphasis on gastrointestinal and pancreatic cancers.
- He currently chairs Hematology and Medical Oncology at Weill Cornell Medicine and previously led hematology at Beth Israel Deaconess Medical Center.
- Director compensation consists of a stock option award and an RSU award, each valued at $362,500, vesting over approximately three years.
- The Company is entering its standard indemnification agreement with Dr. Hidalgo, with the form previously filed as Exhibit 10.8 to the 2018 Form S-1/A.
- The filing discloses no related-party transactions under Item 404(a) and no financial results, guidance, or material financial impact.
03—Questions
Frequently Asked Questions
Does this appointment have a material financial impact on Guardant Health?
Unlikely. The director compensation is two awards valued at $362,500 each, which is modest relative to the Company's operations. The filing contains no financial results, guidance, or transaction disclosures that would affect valuation.
Why is a pancreatic and GI oncology expert joining the board?
The filing does not state a specific rationale beyond the press release, which cites his translational and clinical research expertise in anticancer drug development. This expertise is relevant to Guardant's oncology focus across screening, recurrence monitoring, and treatment selection, but the Company has not tied it to a specific strategic initiative in this filing.
Are there any conflicts of interest or related-party issues?
The Company states there are no transactions involving Dr. Hidalgo that would be reportable under Item 404(a) of Regulation S-K, and no arrangements with other parties under which he was selected. His board seat at Bristol-Myers Squibb is disclosed, but the filing does not describe any relationship between the two companies.
When does Dr. Hidalgo's board term end and when do his equity awards vest?
His term expires at the 2026 Annual Meeting of Stockholders. His initial awards vest 25% on the first anniversary of his appointment, with the remaining 75% vesting monthly over the following three years, subject to continued board service.
04—Continue